Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). (Q46507345)
Jump to navigation
Jump to search
scientific article published in July 2008
Language | Label | Description | Also known as |
---|---|---|---|
English | Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). |
scientific article published in July 2008 |
Statements
1 reference
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). (English)
1 reference
1 reference
Pierfrancesco Tassone
1 reference
Pierosandro Tagliaferri
1 reference
Antonella Fioravanti
1 reference
Maria Teresa Del Vecchio
1 reference
Cinzia Remondo
1 reference
Francesco Montagnani
1 reference
Maria Saveria Rotundo
1 reference
Chiara Ginanneschi
1 reference
Ignazio Martellucci
1 reference
Edoardo Francini
1 reference
Maria Grazia Cusi
1 reference
Guido Francini
1 reference
1 July 2008
1 reference
14
1 reference
13
1 reference
4192-4199
1 reference